Open AccessLenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Author(s) -
Jiayi Wu,
Zhenyu Yin,
Yan Bai,
Yufeng Chen,
Songqiang Zhou,
Shuangjia Wang,
Jianyin Zhou,
Yinan Li,
Funan Qiu,
Bin Li,
Mao-Lin Yan
Publication year - 2021
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s332420
Subject(s) - medicine , hepatocellular carcinoma , transcatheter arterial chemoembolization , adverse effect , gastroenterology , lenvatinib , clinical endpoint , response evaluation criteria in solid tumors , surgery , sorafenib , toxicity , clinical trial , phases of clinical research
Lenvatinib (LEN) combined with anti-PD-1 antibodies (PD-1) exerted promising effects on unresectable hepatocellular carcinoma (uHCC). We assessed the safety and clinical efficacy of triple therapy [LEN+PD-1+transcatheter arterial chemoembolization (TACE)] in uHCC.